Management of Intravenous Immunoglobulin (IVIG) Infusion Reactions

Immediate Recognition and Initial Response

• Stop the IVIG infusion at the first sign of any reaction, keep the IV line patent with normal saline, and call for medical assistance immediately. Position the patient in Trendelenburg for hypotension, upright for respiratory distress, or recovery position if unconscious; provide supplemental oxygen when indicated. 1

Graded Management of Infusion Reactions

Grade 1 – Mild (headache, flushing, mild fever, fatigue, myalgia)

• Reduce the infusion rate to 50 % of the current rate; once symptoms resolve, resume the infusion at 50 % of the original rate and titrate upward as tolerated. 1

Grade 2 – Moderate (moderate headache, chills, nausea, vomiting, urticaria, blood‑pressure changes, tachycardia)

• Stop the infusion temporarily, then administer combined H1 + H2 antihistamines (e.g., diphenhydramine 25‑50 mg IV + ranitidine 50 mg IV), which is superior to H1 antagonists alone.
• Consider a single dose of intravenous corticosteroid (e.g., methylprednisolone 40‑100 mg) for persistent symptoms.
• Monitor vital signs until complete symptom resolution, then restart the infusion at 50 % of the previous rate; if symptoms recur, discontinue the infusion permanently for that session. 1

Grade 3 – Severe (symptomatic bronchospasm, marked dyspnea, hypoxia, severe hypotension, chest pain)

• Permanently stop the infusion for that session.
• Provide aggressive symptomatic treatment:
  
  • Intramuscular epinephrine 0.3‑0.5 mg (1:1000) if anaphylaxis criteria are met.
  • Rapid fluid resuscitation with 1‑2 L normal saline (5‑10 mL/kg in the first 5 min).
  • Combined H1/H2 antihistamines (diphenhydramine 25‑50 mg IV + ranitidine 50 mg IV).
  • Intravenous corticosteroids (methylprednisolone 1‑2 mg/kg IV every 6 h).
  • Bronchodilators for bronchospasm.
  • Atropine 0.6 mg IV for bradycardia.
  • If hypotension persists despite epinephrine and fluids, start a vasopressor infusion (e.g., dopamine 2‑20 µg/kg/min).
• Do not rechallenge during the same session; future IVIG may require desensitization at a specialized center. 1

Grade 4 – Life‑Threatening Anaphylaxis (anaphylaxis, severe respiratory failure, cardiovascular collapse, myocardial infarction)

• Permanently discontinue IVIG.
• Administer intramuscular epinephrine 0.3‑0.5 mg immediately, repeat every 5‑15 min as needed; if response is inadequate, initiate an intravenous epinephrine infusion.
• Give aggressive crystalloid/colloid boluses (20 mL/kg).
• Follow full anaphylaxis resuscitation protocols, including glucagon 1‑5 mg IV over 5 min (followed by infusion) for patients on β‑blockers.
• Never attempt rechallenge without a formal desensitization protocol. 1

Anaphylaxis Criteria and Immediate Treatment

• Epinephrine should be given immediately when any of the following is present:

Post‑Reaction Monitoring and Documentation

• Continuously monitor vital signs until complete symptom resolution.
• Observe patients for a minimum of 24 hours after severe (Grade 3‑4) reactions to detect biphasic anaphylaxis.
• Document reaction grade, specific symptoms, time of onset, interventions performed, and response to treatment. 1

Special Populations and Risk Factors

• Patients with diabetes mellitus, hypertension or other cardiovascular disease, and those receiving concurrent nephrotoxic medications have an increased risk of IVIG‑related complications. 1
• A history of prior thromboembolic events or prolonged immobilization further elevates risk. 2

Critical Pitfalls and Safety Measures

• Do not delay epinephrine administration when anaphylaxis is suspected; it is the only life‑saving medication in true anaphylaxis. 1
• After any reaction, never restart the infusion at the full original rate; always resume at 50 % of the previous rate. 1
• Do not discharge patients prematurely after severe reactions; a 24‑hour observation period is mandatory to capture possible biphasic events. 1
• Corticosteroids provide no acute benefit in anaphylaxis but may help prevent biphasic reactions; they should not be used as sole therapy. 1
• Premedication (acetaminophen, antihistamines, steroids) reduces but does not eliminate infusion reactions; vigilance must be maintained. 1
• Avoid infusion rates > 1.5 mL/kg/h, as higher rates significantly increase reaction frequency. 1
• Ensure adequate hydration before and during infusion, especially when using sucrose‑containing IVIG products, to reduce renal complications. 1

Delayed Adverse Events

• Hemolytic anemia may occur days after infusion; monitor for jaundice, dark urine, and falling hemoglobin levels. 3

Guidelines for Recognizing and Managing IVIG Infusion Reactions

Immediate Recognition and Initial Response

• At the first sign of any IVIG reaction (e.g., vague discomfort, urgency to void, headache, flushing, or vital‑sign changes), the infusion should be stopped immediately, the IV line kept patent with normal saline, and medical assistance called to assess airway, breathing, circulation, and level of consciousness. 4
• Patient positioning should be tailored to the presenting symptom: Trendelenburg for hypotension, upright/sitting for respiratory distress, and recovery position if the patient is unconscious. These positioning recommendations are supported by the same source. 4

Management of Severe (Grade 3–4) Reactions

• For severe or life‑threatening reactions, administer intravenous corticosteroids (e.g., methylprednisolone 1–2 mg/kg every 6 hours) as part of the aggressive symptomatic treatment. 5
• Life‑threatening anaphylaxis requires immediate intramuscular epinephrine 0.3–0.5 mg (1:1000) into the lateral thigh, with repeat dosing every 5–15 minutes as needed. 5

Anaphylaxis Criteria and Clinical Features

• Epinephrine should be given promptly when any of the following is present: acute onset with skin/mucosal involvement (urticaria or angioedema) plus either respiratory compromise or hypotension; or isolated hypotension after IVIG exposure (systolic < 90 mmHg or >30 % drop from baseline).** 5
• Classic anaphylaxis manifestations include flushing, facial swelling, dyspnea, cyanosis, anxiety, nausea, vomiting, malaise, hypotension, loss of consciousness, and possible death, occurring from seconds to hours after infusion. 5

Documentation and Post‑Reaction Monitoring

• All reactions must be documented with the reaction grade, specific symptoms, time of onset, interventions performed, and patient response. 4
• Patients who experience Grade 3–4 reactions should be observed for a minimum of 24 hours to detect biphasic anaphylaxis. (supported by the same source) 4

Special Populations

• Individuals with selective IgA deficiency may possess anti‑IgA antibodies and are at a rare risk of anaphylactic reactions to IVIG. 5
• Some IgA‑deficient patients have successfully tolerated subcutaneous IgG infusions even after a prior IVIG‑related anaphylaxis. 6

Prevention Strategies

• Premedication with acetaminophen, antihistamines, or steroids reduces—but does not eliminate—the incidence of infusion reactions. 5

Delayed Adverse Events

• Aseptic meningitis syndrome can develop within hours to two days after IVIG infusion, presenting with severe headache, neck stiffness, fever, photophobia, and related symptoms; discontinuation of the infusion leads to remission within days without lasting sequelae. 5